AU2023224856A1 - Therapeutic adeno-associated virus for treating pompe disease with long term cessation of gaa enzyme replacement therapy - Google Patents

Therapeutic adeno-associated virus for treating pompe disease with long term cessation of gaa enzyme replacement therapy Download PDF

Info

Publication number
AU2023224856A1
AU2023224856A1 AU2023224856A AU2023224856A AU2023224856A1 AU 2023224856 A1 AU2023224856 A1 AU 2023224856A1 AU 2023224856 A AU2023224856 A AU 2023224856A AU 2023224856 A AU2023224856 A AU 2023224856A AU 2023224856 A1 AU2023224856 A1 AU 2023224856A1
Authority
AU
Australia
Prior art keywords
gaa
administration
ert
aav
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023224856A
Other languages
English (en)
Inventor
Sam HOPKINS
Edward Clinton SMITH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
AskBio Inc
Original Assignee
Duke University
AskBio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University, AskBio Inc filed Critical Duke University
Publication of AU2023224856A1 publication Critical patent/AU2023224856A1/en
Assigned to DUKE UNIVERSITY, AskBio Inc. reassignment DUKE UNIVERSITY Amend patent request/document other than specification (104) Assignors: ASKLEPIOS BIOPHARMACEUTICAL, INC., DUKE UNIVERSITY
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2023224856A 2022-02-25 2023-02-23 Therapeutic adeno-associated virus for treating pompe disease with long term cessation of gaa enzyme replacement therapy Pending AU2023224856A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263314093P 2022-02-25 2022-02-25
US63/314,093 2022-02-25
US202263319034P 2022-03-11 2022-03-11
US63/319,034 2022-03-11
US202263340972P 2022-05-12 2022-05-12
US63/340,972 2022-05-12
PCT/US2023/013713 WO2023164060A2 (en) 2022-02-25 2023-02-23 Therapeutic adeno-associated virus for treating pompe disease with long term cessation of gaa enzyme replacement therapy

Publications (1)

Publication Number Publication Date
AU2023224856A1 true AU2023224856A1 (en) 2024-08-15

Family

ID=87766839

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023224856A Pending AU2023224856A1 (en) 2022-02-25 2023-02-23 Therapeutic adeno-associated virus for treating pompe disease with long term cessation of gaa enzyme replacement therapy

Country Status (8)

Country Link
US (1) US20250163457A1 (https=)
EP (1) EP4482516A4 (https=)
JP (1) JP2025508841A (https=)
CN (1) CN119095612A (https=)
AU (1) AU2023224856A1 (https=)
CA (1) CA3252501A1 (https=)
TW (1) TW202342109A (https=)
WO (1) WO2023164060A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025053118A1 (ja) * 2023-09-04 2025-03-13 アステラス製薬株式会社 短縮型ｃｍｖプロモーター配列、及び／又は短縮型ポリアデニル化配列を含む組換えアデノ随伴ウイルス
WO2025235807A1 (en) * 2024-05-10 2025-11-13 Solid Biosciences, Inc. Compositions and methods to improve graft survival

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001269923A1 (en) * 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US8679478B2 (en) * 2010-10-04 2014-03-25 Duke University Methods of lysosomal storage disease therapy
EP3293259A1 (en) * 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
US20200063160A1 (en) * 2018-08-07 2020-02-27 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type ii
CN113423419A (zh) * 2019-01-04 2021-09-21 桑格摩生物治疗股份有限公司 用于治疗法布里病的方法和组合物
KR20220098384A (ko) * 2019-11-19 2022-07-12 아스클레피오스 바이오파마슈티컬, 인크. 폼페병 및 리소좀 장애를 치료하기 위한 간-특이적 프로모터를 포함하는 치료적 아데노-관련 바이러스
US20250213726A1 (en) * 2022-03-18 2025-07-03 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus using codon optimized nucleic acid encoding alpha-glucosidase (gaa) for treating pompe disease, with signal peptide modifications

Also Published As

Publication number Publication date
US20250163457A1 (en) 2025-05-22
CA3252501A1 (en) 2023-08-31
EP4482516A4 (en) 2026-03-25
JP2025508841A (ja) 2025-04-10
CN119095612A (zh) 2024-12-06
TW202342109A (zh) 2023-11-01
WO2023164060A3 (en) 2023-10-19
EP4482516A2 (en) 2025-01-01
WO2023164060A2 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
US20220347297A1 (en) Methods of permitting a subject to receive multiple doses of recombinant adeno-associated virus
AU2020388634A1 (en) Therapeutic adeno-associated virus comprising liver-specific promoters for treating Pompe disease and lysosomal disorders
JP6266529B2 (ja) Ｃｎｓにおけるアリールスルファターゼａ活性を増加するための方法および組成物
US20220226504A1 (en) Composition for treatment of crigler-najjar syndrome
US20250163457A1 (en) Therapeutic adeno-associated virus for treating pompe disease with long term cessation of gaa enzyme replacement therapy
US20250276093A1 (en) Therapeutic adeno-associated virus using codon optimized nucleic acid encoding factor viii
WO2017106326A1 (en) Aav-anti pcsk9 antibody constructs and uses thereof
TW202144575A (zh) 使用ａａｖ及治療調配物之苯酮尿症治療
Gualtierotti et al. Gene therapy in hemophilia: the dawn of a new era
KR20250005569A (ko) 신호 펩타이드 변형을 갖는, 폼페병을 치료하기 위한 코돈 최적화된 알파-글루코시다제(gaa) 암호화 핵산을 사용하는 치료적 아데노-연관 바이러스
HK40121378A (zh) 用於在长期停止gaa酶替代疗法的情况下治疗庞贝病的治疗性腺相关病毒
WO2025064350A1 (en) Therapeutic adeno-associated virus using nucleic acid encoding alpha-glucosidase (gaa) for treating pompe disease, with heterologous signal peptide
WO2023081781A1 (en) Methods for use of viral vector constructs for the treatment of fabry disease
EP4466367A1 (en) Methods for treatment of ornithine transcarbamylase (otc) deficiency
HK40120720A (zh) 具有信号肽修饰的、使用编码α-葡萄糖苷酶(GAA)的经密码子优化的核酸治疗庞贝氏病的治疗性腺相关病毒
CN118202061A (zh) 使用病毒载体构建体治疗法布里病的方法
HK40087843A (zh) 用於治疗庞贝氏病和溶酶体紊乱的包含肝特异性启动子的治疗性腺相关病毒
WO2025259575A1 (en) Methods and compositions for treatment of duchenne muscular dystrophy

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: DUKE UNIVERSITY

Free format text: FORMER NAME(S): ASKLEPIOS BIOPHARMACEUTICAL, INC. ; DUKE UNIVERSITY

Owner name: ASKBIO INC.

Free format text: FORMER NAME(S): ASKLEPIOS BIOPHARMACEUTICAL, INC. ; DUKE UNIVERSITY